newsfilter
← Earnings
Earnings Releases·

Aquestive Therapeutics — Third Quarter 2026 Earnings Summary

  • Total revenue declined 41% year-over-year to $7.6 million in Q3 2026, driven by lower Suboxone product orders, while net loss widened to $16.5 million ($0.13 per share) compared to $15.4 million in Q3 2025.
  • Full-year 2026 financial guidance remains unchanged, projecting total revenue between $46 million and $50 million and a non-GAAP adjusted EBITDA loss between $30 million and $35 million.
  • In October 2026, the Company granted Eton Pharmaceuticals exclusive U.S. commercialization rights to Libervant, securing a $10 million upfront payment and eligibility for up to $47.5 million in contingent milestones.
  • Key regulatory milestones include a PDUFA goal date of March 16, 2027, for the Anaphylm NDA resubmission, with Health Canada submission expected in Q4 2026 and EU filing planned for Q1 2027.
  • Cash and cash equivalents decreased to $90.3 million as of September 30, 2026, from $121.2 million at year-end 2025, while debt levels increased significantly to $83.8 million total.
Company
AQUESTIVE THERAPEUTICS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic